Clinical Hold

Clinical Hold - Axcellant

Clinical Hold

  1. Feb 28, 2025

What Does ‘Clinical Hold’ Mean?

A clinical hold is a regulatory action taken by the U.S. Food and Drug Administration (FDA) to temporarily suspend or delay a clinical trial. This action is typically implemented when the FDA identifies potential safety concerns or other issues that require further investigation or resolution before the trial can proceed.

During a clinical hold, no new participants can be enrolled in the study, and existing participants must not receive the investigational product. The sponsor of the clinical trial must address the FDA’s concerns and provide additional information or make necessary changes before the hold can be lifted and the trial allowed to continue.

Why Is the ‘Clinical Hold’ Important in Clinical Research?

The term ‘clinical hold’ is crucial in clinical research as it serves as a critical safety mechanism to protect study participants and ensure the integrity of clinical trials. It allows regulatory bodies to intervene when potential risks or concerns arise, ensuring that patient safety remains the top priority throughout the research process.

Understanding clinical holds is essential for sponsors, investigators, and other stakeholders in clinical research to navigate regulatory requirements effectively. It emphasizes the importance of rigorous study design, thorough safety monitoring, and prompt addressing of any issues raised by regulatory authorities to maintain the progress and validity of clinical trials.

Good Practices and Procedures

  1. Establish a rapid response team dedicated to addressing clinical holds, including regulatory affairs specialists, medical experts, and data analysts.
  2. Implement a proactive risk assessment protocol to identify potential issues that could lead to a clinical hold before they arise.
  3. Develop a comprehensive communication plan to keep all stakeholders informed and aligned during a clinical hold situation.
  4. Create a detailed remediation tracking system to monitor progress on addressing FDA concerns and ensure timely resolution.
  5. Conduct regular mock clinical hold scenarios to train staff and test the organization’s readiness to respond effectively.

Related Terms

Resources

Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis

Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…

Axcellant to Attend EANM 2026 in Vienna

Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…